~13yrs of neoadjuvant adventure comes to positive conclusion (for now)! In @NEJM today & presented at #ASCO25 5 yr survival for pts w lung cancer that can be removed by surgery is better with just 3 doses of immunotherapy before the operation! #LCSM 1/ nejm.org/doi/full/10.10… Our 1st study of neoadjuvant anti-PD1 nivolumab in lung cancer ran from 2012-15, 21 brave pts took the leap to enroll in the trial & we found that almost half of them had little or no remaining viable tumor at the time of surgery nejm.org/doi/10.1056/NE…

With the goal of addressing a key clinical question, which pts w lung cancer may benefit from adjuvant immunotherapy after neoadjuvant, today at #WCLC2024 we presented results of an exploratory individual pt level analysis of the #CM77T & #CM816 trials 1/ There has been 1 positive phase 3 neoadj only trial and 3 positive phase 3 perioperative trials in lung cancer. Phase 3 trials comparing the approaches will take years to complete. In the clinic every day pts return after surgery & further adj IO (or not) is the key topic. 2/

Today, CheckMate 816, a phase 3 trial of neoadjuvant chemo + nivolumab immunotherapy was published i - this was a global effort to improve the lives of pts dealing with newly diagnosed surgical lung cancer. nejm.org/doi/full/10.10… This study built on an investigator-initated trial @ChaftJamie @SmithImmunology, @ValsamoA @JulieBrahmer, @dpardol1 & I reported back in 2018. Many others have continued this work with larger phase 2 trials. nejm.org/doi/10.1056/NE…

Today at #AACR21 I was honored to present results of the phase 3 CheckMate 816 neoadjuvant chemo-nivo lung cancer trial on behalf of all the colleagues, patients & families who made it possible. In this thread I will discuss why we did the study, results and next steps/ This study built on an investigator-initated trial @ChaftJamie @SmithImmunology, @JulieBrahmer, @dpardol1 and I (many others have continued this work with larger phase 2 trials) reported back in 2018
nejm.org/doi/10.1056/NE…